Compass Pathways Plc ((CMPS)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Compass Pathways Plc is conducting a Phase III clinical study titled ‘A Phase III, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With Treatment-resistant Depression.’ The study aims to evaluate the effectiveness, safety, and tolerability of the drug COMP360 in individuals suffering from treatment-resistant depression (TRD). This research is significant as it targets a population with limited treatment options, potentially offering a new therapeutic avenue.
The intervention being tested is COMP360, a psilocybin-based drug administered in doses of 25 mg, 10 mg, and 1 mg. The primary purpose of this drug is to alleviate symptoms of depression in patients who have not responded to traditional treatments, with psychological support provided during administration.
The study is designed as a randomized, parallel, double-blind, controlled trial with a primary focus on treatment. It involves 568 participants who are randomly assigned to different dosage groups. The study employs a quadruple masking approach, ensuring that participants, care providers, investigators, and outcomes assessors are unaware of the group assignments to maintain objectivity.
The study began on February 14, 2023, and is currently recruiting participants. The primary completion date is set for July 22, 2025, with the last update submitted on the same date. These timelines are crucial for tracking the study’s progress and anticipating when results might be available.
This clinical study update could influence Compass Pathways’ stock performance by boosting investor confidence in the company’s innovative approach to treating TRD. As the study progresses, positive results could differentiate Compass Pathways from competitors in the mental health treatment space, potentially impacting the broader industry landscape.
The study is ongoing, and further details are available on the ClinicalTrials portal.